EUROPEAN MULTIDISCIPLINARY ON UROLOGICAL CANCERS..

14th European Multidisciplinary Congress on Urological Cancers - EMUC 2022

 

10-13 November 2022 Budapest
Close
N. Poster
Poster title
Applicant name
Status
  P-002 Simultaneous bilateral video-assisted inguinal lymphadenectomy: The best solution? José Pereira Received Received
  O-002 Does metastases-direct therapy guided by PSMA PET/CT really improve oncologic outcomes in oligorecurrent prostate cancer patients? Alessandro Pissavini Received Received
  P-003 Risk of local recurrence in men with Penile Intraepithelial Neoplasia (PeIN) in the surgical margin after penile sparing surgery Christian Fankhauser Received Received
  O-003 Prognosis of primary papillary Ta-G3 bladder cancer in the non-muscle invasive spectrum Irene Beijert Received Received
  O-006 Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study Christian Fankhauser Received Received
  P-013 Immunohistochemical PSMA expression and histology predictors in primary staging high-risk prostate cancer patients studied with PSMA PET/CT Alessandro Pissavini Received Received
  P-019 Characterization of significant prostate cancer invisible and visible in imaging tests Morillo Tejedor Ana Cristina Received Received
  P-025 Description of Castration-Resistant Prostate Cancer with Unknown Metastatic Status (CRPC-MX) population in the real-world AfrODiTA study Alba Quesada-García Received Received
  P-027 Avoiding false-positive MRI results in prostate cancer-suspected men: A step forward towards reducing overdiagnosis Mar Fernandez Salamanca Received Received
  P-029 Comparative study between micro-ultrasonography-guided biopsy (EXACTVUTM) and multiparametric MRI-guided biopsy (KOELISTM system) for prostate cancer diagnosis Esther García Rojo Received Received
  P-033 Genomic classifiers in personalized prostate cancer radiotherapy approaches a systematic review and future perspectives based on international consensus Simon Spohn Received Received
  P-035 Is cribriform pattern in biopsy a risk factor for metastatic disease on 68Ga-PSMA-PET/CT? Joris Heetman Received Received
  P-039 Analysis of the evolution of a real world practice prostate cancer cohort on active surveillance Juan Luis Sanz Miguelañez Received Received
  P-041 Use of BioProtect balloon in patients with low- or intermediate-risk prostate cancer receiving dose-escalated EBRT: A retrospective, single institution study reporting rectal spacing and dosimetry Paulo Costa Received Received
  P-042 Location-based oncological outcomes of sentinel node dissection during radical prostatectomy: Are all sentinel nodes equal? Alessandro Pissavini Received Received
  P-044 Clinical impact of ERG and PTEN alterations in men underwent radical prostatectomy Panagiotis Velissarios Stamatakos Received Received
  P-050 Wait-and-see protocol in patients with biochemical recurrence after robot-assisted radical prostatectomy, with no evidence of disease on restaging PSMA PET/CT Katelijne de Bie Received Received
  P-052 Genetic variants at 8q24 region are associated with prostate cancer susceptibility in a Southeastern European population Panagiotis Vlachostergios Received Received
  P-054 Preliminary results from SIESTA, a pilot observational study investigating sleep quality in prostate cancer patients Fabio Turco Received Received
  P-055 Correlation of claims based and patient reported pad use for incontinence one year after radical prostatectomy Diederik Baas Received Received
  P-058 Long term durable effect of PectaSol-C Modified Citrus Pectin (P-MCP) treatment (tx) in non- metastatic Biochemically Relapsed Prostate Cancer (BRPC-M0) patients (pts): Results of a prospective Phase II Study Daniel Keizman Received Received
  P-059 Radical prostatectomy versus high-dose-rate brachytherapy and hypo-fractionated external beam radiation combined with long-term androgen deprivation for high-risk prostate cancer Keiichiro Mori Received Received
  P-064 Retrospective observational study to assess the treatment pathway and patient journey among men who undergo radiotherapy for high-risk localised and locally advanced prostate cancer in Sweden: ODYSSEY Megan Berger Received Received
  P-069 Identification of clinically significant recurrence patterns in biochemical recurrence after radical prostatectomy and first salvage treatment in patients with prostate cancer using Ga68 PSMA PET-CT Guillermo Barbas Bernardos Received Received
  P-070 Pattern of local recurrence after radical prostatectomy diagnosed on PSMA PET/CT Floor Staal Received Received
  P-072 A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the diagnostic performance of conventional imaging and 18F-PSMA-PET/CT Wietske Luining Received Received
  P-074 Analysis of the frequency of occurrence of mutations in repair genes in patients with prostate cancer in the Republic of Bashkortostan Alexnder Sultanbaev Received Received
  P-075 Local recurrence after salvage post prostatectomy radiotherapy, from palliative to potentially curative? Guillermo Barbas Bernardos Received Received
  P-079 Analysis of PSA response to apalutamide in metastatic castration sensitive prostate cancer Juan Luis Sanz Miguelañez Received Received
  P-080 Testosterone recovery for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study THIERRY SCHULMANN Received Received
  P-081 Oral relugolix for androgen deprivation therapy in advanced prostate cancer: Detailed safety analysis from the randomized phase 3 HERO study THIERRY SCHULMANN Received Received
  P-085 Rash in patients treated with apalutamide in different prostate cancer settings. A real world study Carmen Munoz Calahorro Received Received
  P-091 The impact of PSMA PET/CT on oncologic outcomes of patients with recurrent prostate cancer: The experience of 3 high-volume European centers Alessandro Pissavini Received Received
  P-096 Prognostic factors in the use of immune checkpoint inhibitors for metastatic renal cell carcinoma Hirotaka Nagasaka Received Received
  P-099 Tivozanib as first line treatment for metastatic renal cell carcinoma luis cajal Received Received
  P-101 3D models for surgery planning in renal cell carcinoma with venous thrombus extension. Phase II nct03738488: Predictibility Inés Rivero Belenchón Received Received
  P-102 The role of cytoreductive nephrectomy in the era of immune-combination therapies: A meta-analysis Keiichiro Mori Received Received
  P-103 Re-treatment with immune checkpoint inhibitors in renal cell carcinoma: A systematic review and meta-analysis Panagiotis Vlachostergios Received Received
  P-104 The impact of 3D modeling in surgical planning and outcomes of partial nephrectomy Alessandro Pissavini Received Received
  P-105 3D virtual models for planning percutaneous Cryoablation of small renal masses Alessandro Pissavini Received Received
  P-106 PERC-score as a nephrometry scoring system in percutaneous tumour ablation: Comparison with RENAL, mRENAL, PADUA and SPARE in a multi-centre series Alessandro Pissavini Received Received
  P-110 Impact of the COVID-19 pandemic on kidney cancer care in the Netherlands Hilin Yildirim Received Received
  P-113 Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LENPEMBRO) or sunitinib (SUN) in the CLEAR study Laura Hendrickson Received Received
  P-114 Hereditary renal cell carcinoma surveillance protocols - a review and new surveillance protocol proposal Miguel Miranda Received Received
  P-118 The impact of histology and type of energy used on oncological outcomes after local tumor ablation of small renal masses Alessandro Pissavini Received Received
  P-123 Treatment outcomes of men with stage 2 non-seminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: A systematic review Christian Fankhauser Received Received
  P-124 IMvigor010: Updated analysis of Overall Survival (OS) by circulating tumour DNA (ctDNA) status in patients with post-operative Muscle-Invasive Urothelial Carcinoma (MIUC) treated with atezolizumab Christina ReyesWright Received Received
  P-125 ATM loss and therapeutic vulnerabilities in bladder cancer Kent Mouw Received Received
  P-131 DNA mismatch repair testing in upper tract urothelial carcinoma patients - Is Universal Lynch Syndrome screening necessary? Orlane Figaroa Received Received
  P-132 Evaluation of a cytology-molecular co-test in urine of patients with non-muscle invasive urothelial cancer Panagiotis Vlachostergios Received Received
  P-133 Bladder cancer detection in urine using DNA methylation markers: A prospective preclinical validation Irene Beijert Received Received
  P-139 Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy Guenter Fingerle-Rowson Received Received
  P-149 Avelumab as maintenance treatment in advanced urothelial cancer in the Portuguese population: A multicentric registry analysis Joao Gramaa Received Received
  P-150 Role of neutrophil-to-lymphocytes ratio in predicting non-complete response at 3 months evaluation after BCG induction in non-muscle invasive bladder cancer Daehyuk Chung Received Received
  P-151 Follow-up after kidney sparing surgery in upper tract urothelial carcinoma, an overview of 10 year contemporary data; Do we need to adjust current follow up protocol? Orlane Figaroa Received Received
  P-152 Prognostic value of vascular endothelial growth factor and vascular cell adhesion molecule-1 in bladder carcinoma Keiichiro Mori Received Received
  P-160 Urostoma APPtimize: Improving quality of life of patients having an urostomy by offering personalised and timed guidance in a patient-centred mobile application Noor van Ginkel Received Received
  P-162 COVID-19 pandemic impact in bladder cancer treatment and features José Pereira Received Received
  P-163 Practical approach and surgical outcome to treatment rectourinary fistula in male cancer patients Liliya Tryfonyuk Received Received
  LB-166 VOLGA: Results from the phase 3 safety run-in with durvalumab (D) tremelimumab (T) enfertumab vedotin (EV) fer cisplatin-ineligible muscle-invasive bladder cancer (MIBC) Thomas Powles Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
01:19
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

14th European Multidisciplinary Congress on Urological Cancers - EMUC 2022

 

10-13 November 2022 Budapest
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 10/11/2022 TO 10/11/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert